Merck still sees ‘compelling’ outlook for Terns leukemia drug
Merck still sees ‘compelling’ outlook for Terns leukemia drug
Body unavailable. Use the original source.
Merck still sees ‘compelling’ outlook for Terns leukemia drug
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.